PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a pioneering clinical-stage biotechnology company, has announced promising new survival data from its Phase 2 study involving the innovative Bria-IMT treatment combined with checkpoint inhibitors (CPI) for patients suffering from hormone receptor-positive (HR+) metastatic breast cancer (MBC). This study highlights a significant advancement in treatment options as the results indicate that the median overall survival (OS) of patients treated with Bria-IMT stands at an impressive 17.3 months, which notably outstrips the historical median OS of 14.4 months achieved with the current antibody-drug conjugate (ADC) standard, TRODELVY (sacituzumab govitecan-hziy), in a comparable cohort of heavily pre-treated patients.

In the context of triple-negative breast cancer (TNBC) patients who were also treated with the Bria-IMT regimen, the survival rates observed were comparable to those attained with TRODELVY. Yet, it is crucial to note that these results still reflect a remarkable 70% improvement over standard chemotherapy outcomes in this challenging patient group.

We are truly impressed with the survival benefit data of the regimen that exceeds or meets those of TRODELVY in HR+ and TNBC metastatic breast cancer patients, respectively. Bria-IMT appears to be very well-tolerated, stated Dr. William V. Williams, BriaCells President and CEO. He expressed optimism for the future, stating, We look forward to further confirming this clinical data in our ongoing pivotal Phase 3 study with overall survival as its primary endpoint.

Dr. Giuseppe Del Priore, BriaCells Chief Medical Officer, emphasized the urgency of addressing the therapeutic needs of patients with HR+ and TNBC MBC, who represent a significant portion of the breast cancer demographic. These groups face considerable treatment challenges and have limited options, often with overall survival durations measured in mere months, he noted. The clinical data we have gathered supports our hypothesis that the combination of Bria-IMT and CPI has the potential to fulfill the unmet medical needs of these patients, providing an effective and well-tolerated treatment alternative.

The Phase 2 study involved 54 metastatic breast cancer patients who had undergone a median of six prior lines of therapy. Among these, 37 patients were treated with the formulation currently investigated in BriaCell's ongoing pivotal Phase 3 study, registered under ClinicalTrials.gov (NCT06072612). Remarkably, there have been no reports of treatment-related discontinuations concerning Bria-IMT.

In summary, these findings not only advance BriaCell's mission to transform cancer care through innovative therapies but also provide hope to patients battling these aggressive forms of breast cancer. As the study progresses, the medical community eagerly anticipates further insights that could solidify Bria-IMT's role in the treatment landscape for metastatic breast cancer.

For anyone interested in following BriaCell's journey and advancements in cancer treatment, more information is available on their official website at

www.globenewswire.com
2025-04-16
Profile Image

Angela Thompson